Cardiovascular disease and COVID-19

Wu, 2020, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease Control and prevention, J Am Med Assoc, 10.1001/jama.2020.2648 Xiong, 2020, Coronaviruses and the cardiovascular system: acute and long-term implications, Eur Heart J, 10.1093/eurheartj/ehaa231 Li, 2020, Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China, Clin Res Cardiol, 10.1007/s00392-020-01626-9 Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 10.1016/S0140-6736(20)30566-3 Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Chen, 2020, Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19), medRxiv Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, J Am Med Assoc, 10.1001/jama.2020.1585 Arentz, 2020, Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington state, J Am Med Assoc, 10.1001/jama.2020.4326 Lippi, 2020, Laboratory abnormalities in patients with COVID-2019 infection, Clin Chem Lab Med, 10.1515/cclm-2020-0198 Oudit, 2009, SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS, Eur J Clin Invest, 39, 618, 10.1111/j.1365-2362.2009.02153.x Wu, 2017, Altered lipid metabolism in recovered SARS patients twelve years after infection, Sci Rep, 7, 9110, 10.1038/s41598-017-09536-z Corrales-Medina, 2015, Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease, J Am Med Assoc, 313, 264, 10.1001/jama.2014.18229 Tam, 2020, Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China, Circ Cardiovasc Qual Outcomes, 10.1161/CIRCOUTCOMES.120.006631 Ferrario, 2005, Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation, 111, 2605, 10.1161/CIRCULATIONAHA.104.510461